Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SORBITRATE vs ISORDIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sorbitrate (isosorbide dinitrate) is a nitrate that relaxes vascular smooth muscle by converting to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates coronary arteries and peripheral veins (venodilation > arteriodilation), reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.
Prophylaxis of angina pectoris (to reduce frequency and severity of anginal attacks),Chronic management of angina pectoris (as part of long-term therapy),Off-label: Congestive heart failure (adjunctive therapy to reduce preload and afterload),Off-label: Esophageal spasm (symptomatic relief)
Angina pectoris (prophylaxis and acute treatment),Heart failure (off-label: adjunctive treatment in acute myocardial infarction)
Sublingual: 2.5-5 mg as needed for acute angina, up to 10 mg per episode. Oral (sustained-release): 40-80 mg twice daily (immediate-release: 10-20 mg three times daily).
Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.
Terminal elimination half-life: 5–6 hours. Clinical context: supports dosing every 6–8 hours; requires nitrate-free interval to prevent tolerance.
Terminal half-life: 1–4 hours (isosorbide dinitrate); clinical context: short duration requires frequent dosing or sustained-release formulations.
Isosorbide dinitrate undergoes extensive first-pass metabolism in the liver via glutathione-dependent organic nitrate reductase (likely mediated by mitochondrial aldehyde dehydrogenase, ALDH2) to active metabolites isosorbide-2-mononitrate and isosorbide-5-mononitrate, with the latter being the major active metabolite. These metabolites are further glucuronidated and excreted renally.
Primarily hepatic via glutathione-organic nitrate reductase; also undergoes denitration to active metabolites (isosorbide-2-mononitrate and isosorbide-5-mononitrate).
Renal: ~20% unchanged; remainder as metabolites (isosorbide-2-mononitrate, isosorbide-5-mononitrate). Biliary/fecal: negligible.
Renal: 80% as inactive metabolites; biliary/fecal: 20% as conjugates.
~28% bound to albumin.
~28% bound to albumin.
Vd: 1.5–3.5 L/kg. Clinical meaning: extensive tissue distribution, high uptake in vascular smooth muscle.
2–4 L/kg, indicating extensive tissue distribution.
Sublingual: ~40–60% (bypasses first-pass metabolism). Oral: ~10–20% (extensive first-pass hepatic metabolism).
Sublingual: ~40–60% (first-pass bypassed); oral: <30% due to extensive first-pass hepatic metabolism.
No dose adjustment required. GFR <10 m L/min: limited data, consider reduced dose.
No specific GFR-based dose adjustments are recommended; however, caution is advised in severe renal impairment due to potential accumulation of metabolites.
Child-Pugh A: no adjustment. Child-Pugh B or C: reduce dose by 50% or extend dosing interval.
In Child-Pugh class A: no adjustment. Child-Pugh class B and C: reduce dose by 50% and monitor for hypotension.
Not recommended for children <18 years due to lack of safety data.
Isosorbide dinitrate: not recommended for use in children due to lack of safety and efficacy data; no established pediatric dosing guidelines.
Start at lower end of dosing range (e.g., sublingual 2.5 mg, oral 10 mg twice daily) due to increased sensitivity and risk of hypotension.
Elderly patients may have increased sensitivity to hypotension. Initiate with lowest doses (e.g., 5 mg orally twice daily) and titrate slowly. Monitor blood pressure and orthostatic changes.
No FDA boxed warning.
Do not use in patients with erectile dysfunction medications (PDE-5 inhibitors) due to risk of severe hypotension.
Hypotension: May cause severe hypotension, especially upon standing (orthostatic hypotension). Correct hypovolemia before use.,Tolerance: Continuous use may lead to development of tolerance; a daily nitrate-free interval (10-12 hours) is recommended to maintain efficacy.,Headache: Common, often dose-limiting; may be severe initially but decreases with continued use.,Worsening angina: Abrupt discontinuation may precipitate angina; taper gradually.,Hypertrophic cardiomyopathy: Use with caution in patients with hypertrophic obstructive cardiomyopathy as vasodilation may worsen outflow obstruction.,Increased intracranial pressure: Use with caution in patients with increased intracranial pressure (e.g., head trauma, cerebral hemorrhage).
Hypotension (especially with volume depletion or alcohol),Tolerance with prolonged use (intermittent dosing recommended),Exacerbation of angina upon abrupt withdrawal,Use cautiously in hypertrophic cardiomyopathy
Hypersensitivity to isosorbide dinitrate or any component of the formulation,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension,Severe hypotension (systolic BP < 90 mm Hg),Cardiogenic shock (unless used to maintain coronary perfusion pressure with inotropic support),Obstructive cardiomyopathy (relative contraindication),Increased intracranial pressure (relative contraindication)
Hypersensitivity to nitrates,Concurrent use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil),Severe anemia,Increased intracranial pressure (head trauma, cerebral hemorrhage),Acute circulatory failure (shock, vascular collapse)
No significant food interactions, but high-fat meals may delay absorption. Avoid excessive alcohol, which can cause additive vasodilation and hypotension.
Avoid excessive alcohol consumption. No specific food interactions; however, high-fat meals may delay absorption of oral formulations. Maintain consistent dietary habits to minimize variations in drug effects.
Isosorbide dinitrate (Sorbitrate) has no well-controlled studies in pregnant women. Animal studies have not shown teratogenic effects. Due to vasodilatory effects, there is a potential risk of fetal hypoxia, especially during the second and third trimesters. Use only if clearly needed.
Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. It should be used during pregnancy only if clearly needed. Potential fetal risks include hypotension and reduced uteroplacental perfusion, particularly in the first trimester. Second and third trimester risks are theoretical due to maternal hemodynamic changes. Avoid use near term due to risk of neonatal methemoglobinemia. FDA pregnancy category C.
It is not known if isosorbide dinitrate is excreted in human milk. The M/P ratio is unknown. Because many drugs are excreted in milk, caution should be exercised when administered to a nursing woman.
Excretion in human milk is unknown. Due to potential for serious adverse reactions in nursing infants (e.g., methemoglobinemia), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio not reported.
No specific dose adjustments are recommended, but due to increased plasma volume and altered hemodynamics in pregnancy, lower starting doses may be considered, titrating to clinical response. Monitor for hypotension.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance; however, no specific dose adjustments are established. Use lowest effective dose with careful titration to avoid hypotension. Initiate with 5-10 mg sublingual for acute episodes; for prophylaxis, 10-40 mg orally every 6 hours. Monitor for excessive hypotension.
Sorbitrate (isosorbide dinitrate) is a nitrate vasodilator used for angina prophylaxis, not acute attacks. Sublingual form has faster onset; oral sustained-release provides longer duration. Tolerance develops rapidly with continuous dosing; use a 10-12 hour nitrate-free interval daily. Monitor for hypotension, especially with concurrent PDE-5 inhibitors (e.g., sildenafil) – absolute contraindication due to severe hypotension risk. Headache is common, often transient; advise analgesia. Avoid abrupt discontinuation.
Isordil (isosorbide dinitrate) is a nitrate vasodilator used for angina prophylaxis. Sublingual formulation provides rapid onset for acute attacks; oral sustained-release is for chronic prophylaxis. Tolerance develops with continuous exposure; use a daily nitrate-free interval of 10-12 hours. Avoid use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Monitor for headache, hypotension, and reflex tachycardia.
Take exactly as prescribed, do not stop abruptly.,For sublingual tablets: place under tongue and let dissolve; do not swallow.,Avoid alcohol as it can worsen dizziness and hypotension.,Prolonged use may lead to tolerance; a daily nitrate-free period is important.,Store tablets in original glass container away from heat and moisture.,Do not use within 24 hours of erectile dysfunction drugs like Viagra, Cialis, or Levitra.,Common side effects: headache, flushing, dizziness; contact doctor if severe or persistent.,If chest pain persists after one sublingual dose, call 911 immediately.
Take sublingual isordil at the first sign of an angina attack; sit down before using to avoid dizziness.,For chronic prophylaxis, take as prescribed; do not skip doses to maintain the nitrate-free interval.,Avoid alcohol as it can increase the risk of hypotension and dizziness.,Report any severe headaches, worsening chest pain, or fainting to your healthcare provider immediately.,Never take erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on isordil.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SORBITRATE vs ISORDIL, answered by our medical review team.
SORBITRATE is a Nitrate vasodilator that works by Sorbitrate (isosorbide dinitrate) is a nitrate that relaxes vascular smooth muscle by converting to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates coronary arteries and peripheral veins (venodilation > arteriodilation), reducing preload and afterload, thereby decreasing myocardial oxygen demand.. ISORDIL is a Nitrate Vasodilator that works by Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SORBITRATE and ISORDIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SORBITRATE is: Sublingual: 2.5-5 mg as needed for acute angina, up to 10 mg per episode. Oral (sustained-release): 40-80 mg twice daily (immediate-release: 10-20 mg three times daily).. The standard adult dose of ISORDIL is: Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SORBITRATE and ISORDIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SORBITRATE is classified as Category C. Isosorbide dinitrate (Sorbitrate) has no well-controlled studies in pregnant women. Animal studies have not shown teratogenic effects. Due to vasodilatory effects, there is a poten. ISORDIL is classified as Category C. Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.